

CURRICULUM VITAE

Name	Kyriazopoulou Evdoxia
Date of birth	7 th June 1986
Current position	Assistant Professor of Critical Care, Department of Critical Care, National and Kapodistrian University of Athens, School of Nursing, General Oncological Hospital of Kifisia “Agioli Anargyroi”
Languages	English, French, German, Greek
e-mail	ekyriazopoulou@windowslive.com , ekyri@med.uoa.gr
Medical studies 2004-2010	University of Athens, Medical School, Greece (Grade Excellent)
Medical license	Prefecture of Attiki (3427, 17/8/2010)
M.Sc. 09/2016-04/2019	“Cardiopulmonary Resuscitation”, National and Kapodistrian University of Athens, Medical School
Ph.D. 04/2017-09/2020	National and Kapodistrian University of Athens, Medical School, Attikon University Hospital (Excellent) “A Randomized Prospective Clinical Trial to Assess the Role of Procalcitonin-Guided Antimicrobial Therapy to Reduce Long-Term Infections Sequelae” (Prof. EJ Giamarellos-Bourboulis)
Post-doctoral research 03/2022-12/2024	4 th Department of Internal Medicine and Infectious Diseases, National and Kapodistrian University of Athens, Medical School, Attikon University Hospital “Immune dysregulation in the post-acute Covid syndrome” (Prof. EJ Giamarellos-Bourboulis)

Honors and awards

2023	Top Reviewer, <i>International Journal of Antimicrobial Agents</i>
03/2023	<i>2nd Prize of Best Oral Presentation:</i> “Immunogenicity of a seasonal influenza vaccine among patients with multiple sclerosis under disease modifying therapies: a single-center observational study” Marantos T, Angelakis E, Kyriazopoulou E , Kitsos D, Chondrogianni M, Mpizta G, Voumvourakis K, Tsiodras S. <u>22nd Panhellenic Congress of Infectious Diseases</u> , Athens
05/2022	<i>Award “Sotirios Papastamatis”:</i> «Immune dysregulation after COVID-19 infection: a new clinical entity” Sidiropoulou C, Giamarellos-Bourboulis EJ, Poulakou G, ..., Kyriazopoulou E . <u>48th Panhellenic Congress of Medicine</u> , Athens

- 12/2021 Publication
 “Procalcitonin to Reduce Long-Term Infection-associated adverse events in Sepsis: A Randomized Trial.”
 ranked among the 10 most impacted publications in Critical Care during 2021 in the *American Journal of Respiratory and Critical Care Medicine*.
<https://www.atsjournals.org/page/ajrccm/collections/best-of-2021/critical-care>
- 09/2017 *Poster and Travel Award:*
 “sFlt-1 and PIGF as novel biomarkers of diagnosis and prognosis of Gram-negative sepsis.”
Kyriazopoulou E, et al
17th Congress of the European Shock Society, Paris
- 05/2017 *1st Award “Sotirios Papastamatis”:*
 “Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis.”
Kyriazopoulou E, et al.
43th Panhellenic Congress of Medicine, Athens
- 04/2011- *Grant “Ioannis Kontoleon”,* National and Kapodistrian University of Athens
 09/2013 For the residency in Germany, after exams

Member of

- Hellenic Society of Antimicrobial Chemotherapy
 - ✓ Member of Executive Committee since 01/2024
 - ✓ Lead of the Study Group of Early Career Scientists in Antimicrobial Therapy and Resistance
- International Society of Antimicrobial Chemotherapy - Early Career Working Group
- European Shock Society

Clinical experience

- 05/2026-present Assistant Professor of Critical Care, Department of Critical Care, National and Kapodistrian University of Athens, School of Nursing, General Oncological Hospital of Kifisia “Agioli Anargyroi”
- 06/2021-04/2026 Consultant, 2nd Department of Critical Care Medicine, National and Kapodistrian University of Athens, Medical School
- 01/2021-06/2021 Fellowship in Infectious Diseases - 2nd Department of Internal Medicine and Infectious Diseases Unit, Tzaneio General Hospital of Piraeus
- 01/2020-12/2020 Rural Doctor, Health Center of Itea, Fokida, Greece
- 09/2016-12/2019 Research Associate, 4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School
- 11/2013-07/2016 Resident in Internal Medicine- 4th Department of Internal Medicine and Infectious Diseases, University of Athens, Medical School

04/2011-09/2013 Resident in Internal Medicine- Department of Internal Medicine, SLK Kliniken, Affiliate Hospital of the University of Heidelberg, Heilbronn, Germany

Reviewer of abstracts in international medical congresses

32nd International Congress of Antimicrobial Chemotherapy (ICC) Early Career Symposium, November 2022, Perth Australia

Editor of manuscripts in peer-reviewed medical journals

Frontiers in Medicine (associate editor)

Reviewer of manuscripts in peer-reviewed medical journals

Acta Haematologica, All Life, Annals of Internal Medicine, Annals of Medicine, Antibiotics, Artificial Cells Nanomedicine and Biotechnology, Bioengineered, Biomarker Insights, BMC Cardiovascular Disorders, BMC Geriatrics, BMC Infectious Diseases, BMC Pediatrics, BMC Public Health, BMC Pulmonary Medicine, BMJ Open, Burns and Trauma, Clinical Immunology, Critical Care, Critical Care Medicine, Cytokine, Diagnostics, eLife, ERJ Open Research, European Journal of Internal Medicine, European Journal of Medical Research, Expert Opinion on Pharmacotherapy, Expert Review of Anti-infective Therapy, Frontiers in Immunology, Frontiers in Microbiology, Frontiers in Medicine, Frontiers in Public Health, Future Drug Discovery, Heliyon, Infection, Infection and Drug Resistance, Informatics in Medicine Unlocked, Intensive and Critical Care Nursing, Intensive Care Medicine Experimental, International Immunopharmacology, International Journal of Antimicrobial Agents, International Journal of Cardiology, International Journal of General Medicine, International Journal of Molecular Sciences, iScience, Journal of Critical Care, Journal of Global Antimicrobial Resistance, Journal of Infection and Public Health, Journal of Inflammation Research, Journal of Innate Immunity, Journal of Microbiology Immunology and Infection, Journal of Obstetrics and Gynaecology, Lancet Microbe, Microbiology Spectrum, Microorganisms, Multiple Sclerosis and Related Disorders, Nutrition and Diabetes, Pathogens, Pathogens and Global Health, PLOS Medicine, PLOS One, Pneumonia, Public health reviews, Renal Failure, Respiratory Research, Reviews in Cardiovascular Medicine, Scientific Reports, The Clinical Respiratory Journal, Therapeutic Advances in Neurological Disorders, Therapeutic Hypothermia and Temperature Management, Tropical Medicine and Infectious Disease

Participation in clinical trials (as Sub-Investigator or Monitor)

1. A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/po to Moxifloxacin IV/po for treating Adults Subjects With Community-Acquired Bacterial Pneumonia. NCT02531438, Paratek Pharmaceuticals Inc.

2. An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa. [NCT03001622, InflaRx GmbH](#)
3. A Randomized Prospective Clinical Trial to Assess the Role of Procalcitonin-Guided Antimicrobial Therapy to Reduce Long-Term Infections Sequelae- The PROGRESS Trial. [NCT03333304, Hellenic Institute for the Study of Sepsis](#)
4. Integration of Clinical and Laboratory Information to Generate Technological Advance for the Diagnosis of Sepsis-The Intelligence 2 Trial. [NCT03350113, University of Athens.](#)
5. Prospective Multi-centre Clinical Study to Assess the Clinical Validity of the Heparin Binding Protein to Indicate the Presence and Outcome of Sepsis in Patients with Suspected Infection Following Emergency Department Admission. [NCT03295825, Hellenic Institute for the Study of Sepsis](#)
6. A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-Guerin Vaccination to Prevent Infections of the Elderly-The ACTIVATE Trial. [NCT03296423, Hellenic Institute for the Study of Sepsis and Radboud University](#)
7. Ferrous Acetyl-Aspartate Casein Formulation Evaluation Over Ferrous Sulfate in Iron Deficiency Anemia (ACCESS). [NCT03524651, Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.](#)
8. A suPAR Guided Double-blind Randomized Clinical Trial of Initiation of Antibiotics for Presumed Infection at the Emergency Department. [NCT03717350, Hellenic Institute for the Study of Sepsis.](#)
9. A Personalized Randomized Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis (PROVIDE). [NCT03332225, Hellenic Institute for the Study of Sepsis.](#)
10. A Phase 3, Randomized, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Ridinilazole (200 mg, Bid) for 10 Days With Vancomycin (125 mg, Qid) for 10 Days in the Treatment of Clostridium Difficile Infection (CDI): Ri-CoDIFy 1. [NCT03595553, Summit Therapeutics.](#)
11. Pulse Photoplethysmography as an Early Tool for the Diagnosis of Sepsis: PROUD-1. [NCT04149132, Hellenic Institute for the Study of Sepsis.](#)
12. Personalized Immunotherapy in Sepsis: a Multicentre and Multinational, Double-blind, Double-dummy Randomized Clinical Trial (ImmunoSep). [NCT04990232, Hellenic Institute for the Study of Sepsis.](#)
13. suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE Open-label, Non-randomized Single-arm Trial. [NCT04357366, Hellenic Institute for the Study of Sepsis.](#)
14. suPAR-Guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE-MORE Double-blind, Randomized, Phase III Confirmatory Trial. [NCT04680949, Hellenic Institute for the Study of Sepsis.](#)

Lectures in Congresses: 51 Greek, 14 international

Abstracts in Congresses: 14 Greek, 21 international

Experience and Activities within ESCMID

- Panel Member of ESCMID Guideline: “Dosing of antimicrobials in patients with renal impairment with or without RRT”. In process.
- Member of ESCMID Evidence Review Group since May 2025
- Member of Study Group for Bloodstream Infections, Endocarditis, and Sepsis (ESGBIES), Study Group for Infections in Critically Ill Patients (ESGCIP)
- Faculty in ESCMID course “Antimicrobial use in Intensive Care and the Emergency Department”, online 2024
- Faculty in ESCMID course “Precision Management of Severe Infections and Sepsis: from Translational Research to Clinical Practice”, Athens 2024

List of most relevant publications in peer-reviewed journals

1. **Kyriazopoulou E**, Leventogiannis K, Norrby-Teglund A, Dimopoulos G, Pantazi A, Orfanos S, et al. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. *BMC Med* 2017; 15: 172. **IF 2024: 7,0**
2. Karakike E, **Kyriazopoulou E**, Tsangaris I, Routsis C, Vincent JL, Giamarellos-Bourboulis EJ. The early change of SOFA score as a prognostic marker of 28-day sepsis mortality: analysis through a derivation and a validation cohort. *Crit Care* 2019; 23: 387. **IF 2024: 8,8**
3. **Kyriazopoulou E**, Sinapidis D, Halvatzis S, Velissaris D, Alexiou N, Kosmas V, et al. Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study. *Int J Antimicrob Agents* 2020; 55: 105836. **IF 2024: 4,9**
4. Giamarellos-Bourboulis EJ, Tsilika M, Moorlag S, Antonakos N, Kotsaki A, Domínguez-Andrés J, **Kyriazopoulou E**, et al. Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly. *Cell* 2020; 183: 315-323.e9. **IF 2024: 45,5**
5. **Kyriazopoulou E**, Liaskou-Antoniou L, Adamis G, Panagaki A, Melachroinou N, Drakou E, et al. Procalcitonin to Reduce Long-Term Infection-associated adverse events in Sepsis: A Randomized Trial. *Am J Respir Crit Care Med* 2021; 203: 202-210. **IF 2024: 19,3**
6. **Kyriazopoulou E**, Panagopoulos P, Metallidis S, Dalekos GN, Poulakou G, Gatselis N, et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. *Elife* 2021; 10: e66125. **IF 2024: 6,4**
7. **Kyriazopoulou E**, Karageorgos A, Liaskou-Antoniou L, Koufargyris P, Safarika A, Damoraki G, et al. Biofire® Filmarray® Pneumonia Panel for Severe Lower Respiratory Tract Infections: Subgroup Analysis of a Randomized Clinical Trial. *Infect Dis Ther* 2021; 10: 1437-1449. **IF 2024: 4,7**
8. Karakike E, Giamarellos-Bourboulis EJ, Kyprianou M, Fleischmann-Struzek C, Pletz MW, Netea MG, Reinhart K, **Kyriazopoulou E**. Coronavirus Disease 2019

as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis. *Crit Care Med* 2021; 49: 2042-2057. **IF 2024: 7,7**

9. **Kyriazopoulou E**, Huet T, Cavalli G, Gori A, Kyprianou M, Pickkers P, et al. Effect of anakinra on mortality in COVID-19: a patient level meta-analysis. *Lancet Rheumatol* 2021; 3: e690-e697. **IF 2024: 15,0**
10. **Kyriazopoulou E**, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al. Early treatment of COVID-19 with anakinra guided by urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. *Nat Med* 2021; 27: 1752-1760. **IF 2024: 58,7**
11. Leventogiannis K*, **Kyriazopoulou E***, Antonakos N*, Kotsaki A*, Tsangaris I, Markopoulou D, et al. Towards Personalized Immunotherapy in Sepsis: The PROVIDE Randomized Clinical Trial. *Cell Rep Med* 2022; 3: 100817. **IF 2024: 11,7**
12. **Kyriazopoulou E**, Leventogiannis K, Tavoulareas G, Mainas E, Toutouzas K, Mathas C, et al. Presepsin as a diagnostic and prognostic biomarker of severe bacterial infections and COVID-19. *Sci Rep* 2023; 13: 3814. **IF 2024: 3,8**
13. Marantos T*, **Kyriazopoulou E***, Lekakis V, Voumvourakis KI, Tsiodras S. Immunogenicity and safety of vaccines in multiple sclerosis: A systematic review and meta-analysis. *J Neurol Sci* 2023; 456: 122852. **IF 2024: 3,6**
14. Giamarellos-Bourboulis EJ, Aschenbrenner AC, Bauer M, Bock C, Calandra T, Gat-Viks I, **Kyriazopoulou E**, et al. The pathophysiology of sepsis and precision medicine-based immunotherapy. *Nat Immunol* 2024; 25: 19-28. **IF 2024: 27,7**
15. **Kyriazopoulou E**, Hasin-Brumshtein Y, Midic U, Poulakou G, Milionis H, Metallidis S, et al. Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial. *Crit Care* 2024; 28: 73. **IF 2024: 8,8**
16. **Kyriazopoulou E**, Dalekos GN, Metallidis S, Poulakou G, Papanikolaou IC, Tzavara V, et al. Heparin-binding protein levels predict unfavorable outcome in COVID-19 pneumonia: A post-hoc analysis of the SAVE trial. *Shock* 2024; 61: 395-399. **IF 2024: 2,7**
17. Marantos T, **Kyriazopoulou E**, Angelakis E, Kitsos D, Chondrogianni M, Mpizta G, et al. Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide vaccine in multiple sclerosis patients under disease modifying therapies: a single-center prospective study. *Vaccine* 2024; 42: 126001. **IF 2024: 4,5**
18. **Kyriazopoulou E**, Akinosoglou K, Florou E, Kouriannidi E, Bogosian A, Tsachouridou O, et al. Anakinra efficacy in COVID-19 pneumonia guided by soluble urokinase plasminogen activator receptor: association with the inflammatory burden of the host. *Int J Antimicrob Agents* 2025; 65: 107405. **IF 2024: 4,9**
19. **Kyriazopoulou E***, Stylianakis E*, Damoraki G, Koufargyris P, Kollias I, Katrini K, et al. Procalcitonin-Guided Early Stop of Antibiotics Prevents Gut Inflammation and Preserves Gut Microbiome: Data from the PROGRESS Controlled Trial. *Int J Antimicrob Agents* 2025; 66: 107507. **IF 2024: 4,9**
20. Paramythiotou E*, **Kyriazopoulou E***, Karakike E, Siopi M, Frantzeskaki F, Meletiadiis J, Tsangaris I. Clinical characteristics and outcome of *Candida auris* bloodstream infections during an outbreak in a Greek tertiary academic Intensive Care Unit. *J Hosp Infect* 2025; S0195-6701(25)00089-1. **IF 2024: 3,9**